July 2017—Cynvenio Biosystems announced the availability of ClearID Total Insight Breast Cancer, a liquid biopsy monitoring service for patients in treatment and survivors in remission. This comprehensive assessment of a patient’s biological health is designed to measure immune health status and detect genetic mutations associated with cancer.
Read More »Cell-free DNA purification upgrade, 3/16
March 2016—Cynvenio Biosystems announced the availability of the Concordia cell-free DNA purification sample preparation upgrade for its multi-template analysis LiquidBiopsy platform.
Read More »Cynvenio offers cfDNA purification upgrade
Feb. 16, 2016—Cynvenio Biosystems announced the availability of the Concordia cell-free DNA purification sample preparation upgrade for its multitemplate analysis LiquidBiopsy platform. When coupled with Thermo Fisher Scientific’s Ion Torrent next-generation sequencing systems, Cynvenio’s workflow provides a comprehensive molecular characterization of tumor cell DNA for cancer research samples from a standard blood draw. The Concordia option, which consists of a ...
Read More »Trial starts for breast cancer liquid biopsy test
Jan. 21, 2016—Diagnostics company Cynvenio Biosystems and Korean biotech firm ATGen Global have launched a pilot study to evaluate a new method for early detection of cancer in women who have completed treatment for triple-negative breast cancer and show no radiographic signs of metastases. The new study will use Cynvenio’s ClearID test, based on its liquid biopsy technology, in combination ...
Read More »Cynvenio announces new PD-L1 test
Oct. 29, 2015—Cynvenio Biosystems announced it has developed, validated, and fully implemented a Programmed Death-Ligand 1 assay for circulating tumor cells obtained via its liquid biopsy technology for several tumor subtypes. Unlike most circulating tumor cell technologies which enumerate CTCs, Cynvenio said its multitemplate approach allows for simultaneous isolation of cell-free DNA and CTCs that can be both evaluated for ...
Read More »